RNA-sequencing analysis of esophageal cancer cells under combination therapy using RAC1 inhibitor and cisplatin

The aim of this study is to identify differentially-expressed mRNAs of esophageal cancer cells, namely, KYSE150 and KYSE510 under cisplatin monotherapy, RAC1 inhibitor monotherapy and combination therapy, compared to the control group. Total RNA was extracted 24 hours for sequencing after cells were treated with the drugs. We find that after being treated with RAC1 inhibitor or combination therapy, the glycolysis pathways in both KYSE150 and KYSE510 cells were significantly inhibited, compared to the control group or cisplatin monotherapy. Our study underlines the significance of RAC1 in regulating glycolysis.